Recombinant Alcelaphine herpesvirus 1 Envelope glycoprotein H (gH)

What is Alcelaphine herpesvirus 1 (AlHV-1) glycoprotein H and what is its role in viral infection?

AlHV-1 glycoprotein H (gH) is a conserved envelope glycoprotein encoded by ORF22 that plays a critical role in viral entry into host cells. As a member of the core herpesvirus fusion machinery, gH typically functions in complex with glycoprotein L (gL) and participates in membrane fusion events during viral entry.

Unlike glycoprotein B (gB), which undergoes furin cleavage as demonstrated by proteomic analysis , gH remains intact and contributes to:

• Host cell receptor binding

• Membrane fusion in conjunction with other glycoproteins

• Potential regulation of cell tropism that may influence AlHV-1's ability to cause disease in cattle while remaining asymptomatic in wildebeest

In the context of AlHV-1 pathogenesis, gH likely contributes to the establishment of latent infection in CD8+ T cells, which is essential for MCF development as shown by recent research .

How do expression systems for recombinant AlHV-1 gH affect protein quality and research applications?

Multiple expression systems have been utilized for producing recombinant AlHV-1 gH, each offering distinct advantages and limitations:

The choice of expression system should be determined by the specific research application. For structural studies, bacterial systems may be sufficient for individual domains, while functional studies requiring native conformation would benefit from mammalian expression systems similar to those used for AlHV-1 gB expression in HEK293T cells .

What methodologies are recommended for purification and quality assessment of recombinant AlHV-1 gH?

Successful purification and quality assessment of recombinant AlHV-1 gH requires a multi-step approach:

Purification Strategy:

• Affinity Chromatography: Using tags (e.g., His-tag as in commercial recombinant preparations ) for initial capture

• Size Exclusion Chromatography: To remove aggregates and separate monomeric protein

• Ion Exchange Chromatography: For removing contaminants with different charge properties

Quality Assessment Protocol:

• Purity Analysis:

  • SDS-PAGE with >85% purity standard as indicated in product specifications

  • Western blotting using tag-specific or gH-specific antibodies

• Identity Confirmation:

  • Mass spectrometry peptide mapping, similar to the approach used for AlHV-1 gB

  • N-terminal sequencing

• Structural Integrity Assessment:

  • Circular dichroism to evaluate secondary structure

  • Thermal shift assays to assess stability

  • Limited proteolysis to verify correct folding

• Functional Validation:

  • Cell binding assays

  • Protein-protein interaction studies with potential gL partners

The recombinant protein should be stored with 50% glycerol at -20°C/-80°C with minimized freeze-thaw cycles to maintain quality, as recommended for commercial preparations .

How can recombinant AlHV-1 gH contribute to understanding the pathogenesis of malignant catarrhal fever?

Recombinant AlHV-1 gH serves as a powerful tool for investigating MCF pathogenesis through multiple experimental approaches:

Viral Entry and Cell Tropism Studies:

• Receptor Identification: Using labeled recombinant gH to identify binding partners on susceptible cells

• Entry Inhibition Assays: Testing if anti-gH antibodies or soluble gH can block infection

• Cell Type Susceptibility: Determining which cell types bind recombinant gH, potentially explaining the virus's tropism for CD8+ T cells

Host-Pathogen Interaction Analysis:

• Differential Binding Studies: Comparing gH binding to cells from natural hosts (wildebeest) versus susceptible species (cattle)

• Structure-Function Analysis: Mapping domains important for species-specific interactions

Comparative Virology:

• Strain Comparison: Analyzing differences between pathogenic (C500) and attenuated AlHV-1 gH

• Cross-Species Analysis: Comparing AlHV-1 gH with other MCF-causing viruses like OvHV-2

Latency Establishment:

• Investigation of Initial Events: Determining if gH-mediated entry influences subsequent latent infection

• T Cell Targeting: Exploring how gH contributes to the virus's ability to establish latency in CD8+ T cells, which is essential for MCF induction

These approaches could provide insights into why AlHV-1 causes fatal disease in cattle but not in its natural wildebeest host, potentially identifying new intervention targets.

What structural and functional relationships exist between AlHV-1 gH and other herpesvirus glycoproteins?

AlHV-1 gH shares structural and functional relationships with glycoproteins from other herpesviruses while maintaining unique characteristics:

Structural Comparisons:

• Domain Organization: Like other herpesvirus gH proteins, AlHV-1 gH likely contains three conserved domains with specific functions in entry

• Glycosylation Patterns: AlHV-1 gH contains predicted N-linked glycosylation sites that may differ from other gammaherpesviruses, potentially affecting receptor specificity

• Transmembrane Region: Contains a typical C-terminal transmembrane domain followed by a short cytoplasmic tail

Functional Conservation:

• Entry Complex Formation: Functions as part of the core entry machinery with gB and gL, similar to all herpesviruses

• Fusion Regulation: Likely controls conformational changes in gB that drive membrane fusion, a conserved function across the herpesvirus family

Unique Features of AlHV-1 Glycoproteins:

• MCF-Specific Glycoproteins: AlHV-1 encodes unique glycoproteins A7 and A8 that regulate viral spread

• A7/A8 Interaction: These glycoproteins are orthologs of Epstein-Barr virus gp42 and gp350 , suggesting they may interact with gH during entry

• Cell-to-Cell Spread: A7 mediates cell-to-cell spread while A8 is necessary for cell-free viral propagation

Understanding these relationships helps contextualize gH function within the broader viral entry process and may explain the unique pathogenesis of AlHV-1.

What techniques are most effective for studying AlHV-1 gH interactions with host cell receptors?

Investigating AlHV-1 gH-receptor interactions requires a comprehensive toolkit of biochemical, cellular, and biophysical techniques:

Protein-Protein Interaction Methods:

• Surface Plasmon Resonance (SPR): Measures real-time binding kinetics between purified recombinant gH and potential receptors

• Co-immunoprecipitation: Identifies host proteins that interact with gH, potentially using tagged recombinant gH as bait

• Proximity Labeling: Utilizes techniques like BioID or APEX2 to identify proteins in close proximity to gH on the cell surface

Cell-Based Approaches:

• Flow Cytometry: Similar to approaches used with AlHV-1 gB , fluorescently labeled recombinant gH can detect binding to different cell types

• Fluorescence Microscopy: Visualizes gH localization and co-localization with potential receptors

• Cell-Cell Fusion Assays: Measures fusion activity when gH is expressed with other viral glycoproteins

Genetic Screening:

• CRISPR-Cas9 Screens: Identifies host factors required for AlHV-1 entry

• cDNA Library Screening: Determines which human genes can confer susceptibility to gH binding in non-permissive cells

Structural Biology:

• Cryo-Electron Microscopy: Visualizes gH-receptor complexes at near-atomic resolution

• X-ray Crystallography: Determines precise binding interfaces between gH and receptor fragments

• Hydrogen-Deuterium Exchange Mass Spectrometry: Maps regions of gH that undergo conformational changes upon receptor binding

These approaches have successfully identified entry receptors for other gammaherpesviruses and can be adapted to study AlHV-1 gH, potentially explaining its species-specific pathogenicity.

How might recombinant AlHV-1 gH be utilized in vaccine development against malignant catarrhal fever?

Recombinant AlHV-1 gH offers multiple strategic opportunities for MCF vaccine development:

Subunit Vaccine Approaches:

• Glycoprotein Combinations: Recombinant gH alone or combined with other viral glycoproteins (particularly gB, which has been identified as a potential vaccine antigen )

• Rationally Designed Antigens: Structure-guided modifications to enhance immunogenicity or stability

• Epitope-Focused Design: Identification and presentation of neutralizing epitopes from gH

Chimeric Virus Strategies:

• Glycoprotein Exchange: Similar to the AlHV-1/OvHV-2 chimeric virus approach where AlHV-1 gB was replaced with OvHV-2 gB , gH could be exchanged to develop cross-protective vaccines

• Attenuated Virus Platforms: Integration of modified gH into attenuated virus backbones, such as AlHV-1 ΔORF73, which fails to establish latency but can still replicate

Immunization Strategies:

• Prime-Boost Protocols: DNA vaccines encoding gH followed by recombinant protein boosting

• Adjuvant Optimization: Testing various adjuvant systems to enhance immune responses to recombinant gH

• Delivery Systems: Nanoparticles, virus-like particles, or liposomes displaying gH

Safety and Efficacy Considerations:

• Correlates of Protection: Establishing whether anti-gH antibodies correlate with protection

• Cross-Protection: Determining if immunity against AlHV-1 gH provides protection against related MCF viruses

• Duration of Immunity: Monitoring longevity of immune responses to recombinant gH formulations

The development of an effective MCF vaccine would benefit from comparative studies with the attenuated AlHV-1 strain that has lost pathogenicity through passage in culture , potentially identifying specific modifications to gH that contribute to attenuation while maintaining immunogenicity.

What methodological approaches can detect conformational changes in AlHV-1 gH during the viral entry process?

Studying the dynamic conformational changes of AlHV-1 gH during viral entry requires sophisticated techniques that can capture transient structural states:

Biophysical Methods:

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS): Measures solvent accessibility changes in different regions of gH under various conditions

• Single-Molecule FRET: Detects distance changes between fluorescently labeled regions of gH during conformational transitions

• Electron Paramagnetic Resonance (EPR): Measures mobility and proximity changes in spin-labeled gH

Structural Biology Approaches:

• Cryo-Electron Microscopy: Captures different conformational states of gH/gL complexes

• Time-Resolved X-ray Structures: Obtains structures of gH at different stages of the fusion process

• Small-Angle X-ray Scattering (SAXS): Monitors global conformational changes in solution

Biochemical Techniques:

• Limited Proteolysis: Different conformational states expose different protease cleavage sites

• Monoclonal Antibody Binding: Conformation-specific antibodies that recognize pre- or post-fusion states

• Cross-linking Mass Spectrometry: Identifies regions that come into proximity during conformational changes

Computational Methods:

• Molecular Dynamics Simulations: Models conformational transitions based on experimental structures

• Normal Mode Analysis: Predicts intrinsic flexibility and potential conformational changes

These approaches could reveal how AlHV-1 gH transitions between pre-fusion and activated states, potentially identifying unique features that contribute to its role in MCF pathogenesis compared to other herpesvirus gH proteins.

How do genes A7 and A8 interact with AlHV-1 gH during viral entry and what are the implications for MCF pathogenesis?

The interaction between AlHV-1 gH and the unique glycoproteins encoded by genes A7 and A8 represents a critical aspect of viral pathogenesis with significant implications for MCF:

Functional Relationships:

• Complementary Roles: Research has demonstrated that A7 mediates cell-to-cell spread while A8 facilitates cell-free viral propagation

• Orthologs of EBV Proteins: A7 and A8 are orthologs of Epstein-Barr virus gp42 and gp350 , which regulate cell tropism switching

• Essential for MCF: Both A7 and A8 are essential for the induction of MCF in experimental models

Mechanistic Interactions:

• Entry Complex Formation: A7 and A8 may function alongside gH/gL during viral attachment and entry

• Cell Type Specificity: The interaction between these glycoproteins may determine which cell types are infected

• Conformational Regulation: A7/A8 might influence gH conformational changes during the entry process

Research Approaches to Study Interactions:

• Co-immunoprecipitation: To detect physical associations between gH and A7/A8

• Functional Complementation: Testing whether recombinant gH can restore function to viruses with A7/A8 mutations

• Cross-linking Studies: Identifying proximity relationships between these proteins on the virion surface

Implications for MCF Pathogenesis:

• Tissue Tropism: The interaction may explain the specific targeting of CD8+ T cells for latent infection

• Species Specificity: Differences in receptor recognition by this glycoprotein complex might contribute to disease in cattle but not wildebeest

• Therapeutic Targets: Disrupting these interactions could represent a novel intervention strategy

The proteomic analysis of virulent and attenuated AlHV-1 found that A8 was detected in virulent virus preparations but was absent from the attenuated virus , suggesting its importance in pathogenesis and highlighting the need to study its interaction with gH.

What role do post-translational modifications play in recombinant AlHV-1 gH function, and how can they be properly replicated in experimental systems?

Post-translational modifications (PTMs) critically influence AlHV-1 gH function, and replicating them correctly presents a significant challenge in recombinant expression systems:

Critical PTMs for gH Function:

Expression Systems for Proper PTMs:

• Mammalian Expression Systems:

  • HEK293T cells (used for AlHV-1 gB ) provide native-like glycosylation

  • CHO cells offer robust production with human-like glycosylation

  • Limitations include lower yields and higher costs

• Advanced Yeast Systems:

  • Glycoengineered Pichia pastoris strains with humanized glycosylation pathways

  • Achieves higher yields than mammalian cells with improved glycosylation

  • Represents a compromise between yield and modification quality

• Insect Cell Systems:

  • Baculovirus expression with engineered insect cells for complex glycosylation

  • SweetBac technology for mammalian-type glycosylation

  • Offers higher yields than mammalian cells with reasonable glycosylation

Verification Approaches:

• Glycoproteomic Analysis: Comparing recombinant gH glycosylation to virus-derived gH

• Functional Assays: Testing receptor binding and fusion activity

• Epitope Mapping: Using conformation-specific antibodies to verify proper folding

Understanding and replicating the correct PTMs on recombinant AlHV-1 gH is essential for studying its authentic function and developing effective vaccine candidates that present native epitopes to the immune system.